Local anesthetics and immunotherapy: a novel combination to fight cancer.
Anesthesia
Cancer
Immunotherapy
Oncolysis
Journal
Seminars in immunopathology
ISSN: 1863-2300
Titre abrégé: Semin Immunopathol
Pays: Germany
ID NLM: 101308769
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
15
07
2022
accepted:
17
08
2022
medline:
25
4
2023
pubmed:
1
9
2022
entrez:
31
8
2022
Statut:
ppublish
Résumé
Intratumoral injection of oncolytic agents such as modified herpes simplex virus T-VEC or local administration of non-viral oncolytic therapies (such as radiofrequency, chemoembolization, cryoablation, or radiotherapy) can activate an anticancer immune response and hence trigger abscopal effects reducing secondary lesions. Preliminary data suggested that oncolytic treatments modulate tumor-infiltrating immune effectors and can be advantageously combined with the immune checkpoint inhibitors. Recent findings indicate that local anesthetics, which are usually used in the clinics to control surgical pain, also possess antineoplastic effects mimicking oncolytic treatments if they are injected into malignant lesions. Moreover, the association of local anesthetics with systemic immune checkpoint inhibition significantly improved overall survival in several preclinical tumor models. This may be explained by direct cytotoxic activity of local anesthetics and additional immune-related abscopal effects. We also summarize the molecular and cellular mechanisms by which the combination of local anesthetics and immunotherapy improves tumor control by the immune system.
Identifiants
pubmed: 36044068
doi: 10.1007/s00281-022-00960-6
pii: 10.1007/s00281-022-00960-6
doi:
Substances chimiques
Anesthetics, Local
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-272Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334(6062):1573–1577. https://doi.org/10.1126/science.1208347
doi: 10.1126/science.1208347
pubmed: 22174255
Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72. https://doi.org/10.1146/annurev-immunol-032712-100008
doi: 10.1146/annurev-immunol-032712-100008
pubmed: 23157435
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059. https://doi.org/10.1038/nm1622
doi: 10.1038/nm1622
pubmed: 17704786
Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S et al (2014) Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 21(1):79–91. https://doi.org/10.1038/cdd.2013.75
doi: 10.1038/cdd.2013.75
pubmed: 23852373
Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15(10):1170–1178. https://doi.org/10.1038/nm.2028
doi: 10.1038/nm.2028
pubmed: 19767732
Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28(5):578–590. https://doi.org/10.1038/emboj.2009.1
doi: 10.1038/emboj.2009.1
pubmed: 19165151
pmcid: 2657583
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61. https://doi.org/10.1038/nm1523
doi: 10.1038/nm1523
pubmed: 17187072
Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S et al (2018) eIF2alpha phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ 25(8):1375–1393. https://doi.org/10.1038/s41418-017-0044-9
doi: 10.1038/s41418-017-0044-9
pubmed: 29358668
pmcid: 6113215
Korbelik M, Zhang W, Merchant S (2011) Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer immunology, immunotherapy : CII 60(10):1431–1437. https://doi.org/10.1007/s00262-011-1047-x
doi: 10.1007/s00262-011-1047-x
pubmed: 21644033
Garg AD, Krysko DV, Vandenabeele P, Agostinis P (2012) Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother : Cii 61(2):215–221. https://doi.org/10.1007/s00262-011-1184-2
doi: 10.1007/s00262-011-1184-2
pubmed: 22193987
Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M et al (2008) The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15(9):1499–1509. https://doi.org/10.1038/cdd.2008.67
doi: 10.1038/cdd.2008.67
pubmed: 18464797
Reschke R, Gajewski TF (2022) CXCL9 and CXCL10 bring the heat to tumors. Science immunology 7(73):1–3. https://doi.org/10.1126/sciimmunol.abq6509
doi: 10.1126/sciimmunol.abq6509
Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D et al (2016) Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Can Res 76(7):1746–1756. https://doi.org/10.1158/0008-5472.CAN-15-1142
doi: 10.1158/0008-5472.CAN-15-1142
Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642–662. https://doi.org/10.1038/nrd4663
doi: 10.1038/nrd4663
pubmed: 26323545
pmcid: 7097180
Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J et al (2018) Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol : Off J Am Soc Clin Oncol 36(17):1658–1667. https://doi.org/10.1200/JCO.2017.73.7379
doi: 10.1200/JCO.2017.73.7379
Yu Z, Geng J, Zhang M, Zhou Y, Fan Q, Chen J (2014) Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death. Oncotarget 5(15):6526–6539. https://doi.org/10.18632/oncotarget.2310
doi: 10.18632/oncotarget.2310
pubmed: 25153727
pmcid: 4171648
Tselikas L, Dardenne A, de Baere T, Faron M, Ammari S, Farhane S et al (2022) Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy’s initial experience with its first 100 patients. Eur J Cancer 172:1–12. https://doi.org/10.1016/j.ejca.2022.05.024
doi: 10.1016/j.ejca.2022.05.024
pubmed: 35724442
Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C et al (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24(12):1845–1851. https://doi.org/10.1038/s41591-018-0232-2
doi: 10.1038/s41591-018-0232-2
pubmed: 30397353
pmcid: 6286242
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O et al (2017) Oncolytic virotherapy promotes intratumoral t cell infiltration and improves Anti-PD-1 immunotherapy. Cell 170(6):1109-19e10. https://doi.org/10.1016/j.cell.2017.08.027
doi: 10.1016/j.cell.2017.08.027
pubmed: 28886381
pmcid: 8034392
Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X et al (2016) PD-1 Blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res : Off J Am Assoc Cancer Res 22(5):1173–1184. https://doi.org/10.1158/1078-0432.CCR-15-1352
doi: 10.1158/1078-0432.CCR-15-1352
Kleinovink JW, Fransen MF, Lowik CW, Ossendorp F (2017) Photodynamic-immune checkpoint therapy eradicates local and distant tumors by CD8(+) T cells. Cancer Immunol Res 5(10):832–838. https://doi.org/10.1158/2326-6066.CIR-17-0055
doi: 10.1158/2326-6066.CIR-17-0055
pubmed: 28851692
O’Shaughnessy MJ, Murray KS, La Rosa SP, Budhu S, Merghoub T, Somma A et al (2018) Systemic antitumor immunity by PD-1/PD-L1 inhibition is potentiated by vascular-targeted photodynamic therapy of primary tumors. Clin Cancer Res : Off J Am Assoc Cancer Res 24(3):592–599. https://doi.org/10.1158/1078-0432.CCR-17-0186
doi: 10.1158/1078-0432.CCR-17-0186
Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L et al (2012) Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Can Res 72(2):430–439. https://doi.org/10.1158/0008-5472.CAN-11-1782
doi: 10.1158/0008-5472.CAN-11-1782
Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G et al (2015) Assessing a novel immuno-oncology-based combination therapy: ipilimumab plus electrochemotherapy. Oncoimmunology 4(6):e1008842. https://doi.org/10.1080/2162402X.2015.1008842
doi: 10.1080/2162402X.2015.1008842
pubmed: 26155423
pmcid: 4485758
Taylor A, McLeod G (2020) Basic pharmacology of local anaesthetics. BJA education 20(2):34–41. https://doi.org/10.1016/j.bjae.2019.10.002
doi: 10.1016/j.bjae.2019.10.002
pubmed: 33456928
Heavner JE (2007) Local anesthetics. Curr Opin Anaesthesiol 20(4):336–342. https://doi.org/10.1097/ACO.0b013e3281c10a08
doi: 10.1097/ACO.0b013e3281c10a08
pubmed: 17620842
Bourne E, Wright C, Royse C (2010) A review of local anesthetic cardiotoxicity and treatment with lipid emulsion. Local Reg Anesth 3:11–19. https://doi.org/10.2147/lra.s8814
doi: 10.2147/lra.s8814
pubmed: 22915863
pmcid: 3417942
Verlinde M, Hollmann MW, Stevens MF, Hermanns H, Werdehausen R, Lirk P (2016) Local anesthetic-induced neurotoxicity. Int J Mol Sci 17(3):339. https://doi.org/10.3390/ijms17030339
doi: 10.3390/ijms17030339
pubmed: 26959012
pmcid: 4813201
Perez-Castro R, Patel S, Garavito-Aguilar ZV, Rosenberg A, Recio-Pinto E, Zhang J et al (2009) Cytotoxicity of local anesthetics in human neuronal cells. Anesth Analg 108(3):997–1007. https://doi.org/10.1213/ane.0b013e31819385e1
doi: 10.1213/ane.0b013e31819385e1
pubmed: 19224816
Aburawi EH, Souid AK (2014) Inhibition of murine cardiomyocyte respiration by amine local anesthetics. Eur J Drug Metab Pharmacokinet 39(4):293–299. https://doi.org/10.1007/s13318-013-0159-4
doi: 10.1007/s13318-013-0159-4
pubmed: 24254523
Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ (2008) Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 109(2):180–187. https://doi.org/10.1097/ALN.0b013e31817f5b73
doi: 10.1097/ALN.0b013e31817f5b73
pubmed: 18648226
Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI (2006) Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 105(4):660–664. https://doi.org/10.1097/00000542-200610000-00008
doi: 10.1097/00000542-200610000-00008
pubmed: 17006061
Weng M, Chen W, Hou W, Li L, Ding M, Miao C (2016) The effect of neuraxial anesthesia on cancer recurrence and survival after cancer surgery: an updated meta-analysis. Oncotarget 7(12):15262–15273. https://doi.org/10.18632/oncotarget.7683
doi: 10.18632/oncotarget.7683
pubmed: 26918830
pmcid: 4924785
Sun Y, Li T, Gan TJ (2015) The effects of perioperative regional anesthesia and analgesia on cancer recurrence and survival after oncology surgery: a systematic review and meta-analysis. Reg Anesth Pain Med 40(5):589–598. https://doi.org/10.1097/AAP.0000000000000273
doi: 10.1097/AAP.0000000000000273
pubmed: 26263074
Chen WK, Miao CH (2013) The effect of anesthetic technique on survival in human cancers: a meta-analysis of retrospective and prospective studies. PLoS ONE 8(2):e56540. https://doi.org/10.1371/journal.pone.0056540
doi: 10.1371/journal.pone.0056540
pubmed: 23437162
pmcid: 3577858
Schlagenhauff B, Ellwanger U, Breuninger H, Stroebel W, Rassner G, Garbe C (2000) Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res 10(2):165–169
doi: 10.1097/00008390-200004000-00009
pubmed: 10803717
de Oliveira GS, Ahmad S Jr, Schink JC, Singh DK, Fitzgerald PC, McCarthy RJ (2011) Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery. Reg Anesth Pain Med 36(3):271–7
doi: 10.1097/AAP.0b013e318217aada
pubmed: 21519312
Gupta A, Bjornsson A, Fredriksson M, Hallbook O, Eintrei C (2011) Reduction in mortality after epidural anaesthesia and analgesia in patients undergoing rectal but not colonic cancer surgery: a retrospective analysis of data from 655 patients in central Sweden. Br J Anaesth 107(2):164–170. https://doi.org/10.1093/bja/aer100
doi: 10.1093/bja/aer100
pubmed: 21586443
Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W (2011) Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth 106(6):814–822. https://doi.org/10.1093/bja/aer055
doi: 10.1093/bja/aer055
pubmed: 21436156
Li T, Chen L, Zhao H, Wu L, Masters J, Han C et al (2019) Both bupivacaine and levobupivacaine inhibit colon cancer cell growth but not melanoma cells in vitro. J Anesth 33(1):17–25. https://doi.org/10.1007/s00540-018-2577-6
doi: 10.1007/s00540-018-2577-6
pubmed: 30426213
Bezu L, Wu Chuang A, Sauvat A, Humeau J, Xie W, Cerrato G et al (2022) Local anesthetics elicit immune-dependent anticancer effects. J Immunother Cancer 10(4):1–17. https://doi.org/10.1136/jitc-2021-004151
doi: 10.1136/jitc-2021-004151
Zhang L, Hu R, Cheng Y, Wu X, Xi S, Sun Y et al (2017) Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A. Cell proliferation 50(5):1–8. https://doi.org/10.1111/cpr.12364
doi: 10.1111/cpr.12364
Li C, Gao S, Li X, Li C, Ma L (2018) Procaine inhibits the proliferation and migration of colon cancer cells through inactivation of the ERK/MAPK/FAK pathways by regulation of RhoA. Oncol Res 26(2):209–217. https://doi.org/10.3727/096504017X14944585873622
doi: 10.3727/096504017X14944585873622
pubmed: 28492141
pmcid: 7844744
D’Agostino G, Saporito A, Cecchinato V, Silvestri Y, Borgeat A, Anselmi L et al (2018) Lidocaine inhibits cytoskeletal remodelling and human breast cancer cell migration. Br J Anaesth 121(4):962–968. https://doi.org/10.1016/j.bja.2018.07.015
doi: 10.1016/j.bja.2018.07.015
pubmed: 30236259
Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145.BMC cancer. 2019;19(1):233.doi: https://doi.org/10.1186/s12885-019-5431-9
Qin A, Liu Q, Wang J (2020) Ropivacaine inhibits proliferation, invasion, migration and promotes apoptosis of papillary thyroid cancer cells via regulating ITGA2 expression. Drug Dev Res 81(6):700–707. https://doi.org/10.1002/ddr.21671
doi: 10.1002/ddr.21671
pubmed: 32314406
Villar-Garea A, Fraga MF, Espada J, Esteller M (2003) Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 63(16):4984–4989
pubmed: 12941824
Li YC, Wang Y, Li DD, Zhang Y, Zhao TC, Li CF (2018) Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer. J Cell Biochem 119(2):2440–2449. https://doi.org/10.1002/jcb.26407
doi: 10.1002/jcb.26407
pubmed: 28926119
Tada M, Imazeki F, Fukai K, Sakamoto A, Arai M, Mikata R et al (2007) Procaine inhibits the proliferation and DNA methylation in human hepatoma cells. Hep Intl 1(3):355–364. https://doi.org/10.1007/s12072-007-9014-5
doi: 10.1007/s12072-007-9014-5
Lirk P, Hollmann MW, Fleischer M, Weber NC, Fiegl H (2014) Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid in breast cancer cells in vitro. Br J Anaesth 113(Suppl 1):i32–i38. https://doi.org/10.1093/bja/aeu201
doi: 10.1093/bja/aeu201
pubmed: 24946779
Chen D, Yan Y, Xie J, Pan J, Chen Y, Li Q et al (2020) Amide-type local anesthetics may suppress tumor cell proliferation and sensitize human hepatocellular carcinoma cells to cisplatin via upregulation of RASSF1A expression and demethylation. J Cancer 11(24):7312–7319. https://doi.org/10.7150/jca.46630
doi: 10.7150/jca.46630
pubmed: 33193895
pmcid: 7646167
Lirk P, Berger R, Hollmann MW, Fiegl H (2012) Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro. Br J Anaesth 109(2):200–207. https://doi.org/10.1093/bja/aes128
doi: 10.1093/bja/aes128
pubmed: 22542536
Xia W, Wang L, Yu D, Mu X, Zhou X (2019) Lidocaine inhibits the progression of retinoblastoma in vitro and in vivo by modulating the miR520a3p/EGFR axis. Mol Med Rep 20(2):1333–1342. https://doi.org/10.3892/mmr.2019.10363
doi: 10.3892/mmr.2019.10363
pubmed: 31173241
pmcid: 6625385
Ying B, Huang H, Li H, Song M, Wu S, Ying H (2017) Procaine inhibits proliferation and migration and promotes cell apoptosis in osteosarcoma cells by upregulation of MicroRNA-133b. Oncol Res 25(9):1463–70. https://doi.org/10.3727/096504017X14878518291077
doi: 10.3727/096504017X14878518291077
pubmed: 28251881
pmcid: 7841045
Yin D, Liu L, Shi Z, Zhang L, Yang Y (2020) Ropivacaine inhibits cell proliferation, migration and invasion, whereas induces oxidative stress and cell apoptosis by circSCAF11/miR-145-5p axis in glioma. Cancer management and research 12:11145–11155. https://doi.org/10.2147/CMAR.S274975
doi: 10.2147/CMAR.S274975
pubmed: 33173347
pmcid: 7648566
Zhang H, Lin J, Hu T, Ren Z, Wang W, He Q (2019) Effect of miR-132 on bupivacaine-induced neurotoxicity in human neuroblastoma cell line. J Pharmacol Sci 139(3):186–192. https://doi.org/10.1016/j.jphs.2019.01.014
doi: 10.1016/j.jphs.2019.01.014
pubmed: 30850243
Sun H, Sun Y (2019) Lidocaine inhibits proliferation and metastasis of lung cancer cell via regulation of miR-539/EGFR axis. Artif cells nanomed biotechnol 47(1):2866–2874. https://doi.org/10.1080/21691401.2019.1636807
doi: 10.1080/21691401.2019.1636807
pubmed: 31299862
Zhang N, Xing X, Gu F, Zhou G, Liu X, Li B (2020) Ropivacaine inhibits the growth, migration and invasion of gastric cancer through attenuation of WEE1 and P13K/AKT signaling via miR-520a-3p. OncoTargets and therapy 13:5309–21
doi: 10.2147/OTT.S244550
pubmed: 32606749
pmcid: 7294106
Arita K, Utsumi T, Kato A, Kanno T, Kobuchi H, Inoue B et al (2000) Mechanism of dibucaine-induced apoptosis in promyelocytic leukemia cells (HL-60). Biochem Pharmacol 60(7):905–915. https://doi.org/10.1016/s0006-2952(00)00406-8
doi: 10.1016/s0006-2952(00)00406-8
pubmed: 10974198
Tsuchiya H, Mizogami M, Ueno T, Shigemi K (2012) Cardiotoxic local anesthetics increasingly interact with biomimetic membranes under ischemia-like acidic conditions. Biol Pharm Bull 35(6):988–992. https://doi.org/10.1248/bpb.35.988
doi: 10.1248/bpb.35.988
pubmed: 22687545
Johnson ME, Uhl CB, Spittler KH, Wang H, Gores GJ (2004) Mitochondrial injury and caspase activation by the local anesthetic lidocaine. Anesthesiology 101(5):1184–1194. https://doi.org/10.1097/00000542-200411000-00019
doi: 10.1097/00000542-200411000-00019
pubmed: 15505455
Dan J, Gong X, Li D, Zhu G, Wang L, Li F (2018) Inhibition of gastric cancer by local anesthetic bupivacaine through multiple mechanisms independent of sodium channel blockade. Biomed Pharmacotherapy = Biomed Pharmacotherapie 103:823–8. https://doi.org/10.1016/j.biopha.2018.04.106
doi: 10.1016/j.biopha.2018.04.106
Lu J, Xu SY, Zhang QG, Xu R, Lei HY (2011) Bupivacaine induces apoptosis via mitochondria and p38 MAPK dependent pathways. Eur J Pharmacol 657(1–3):51–58. https://doi.org/10.1016/j.ejphar.2011.01.055
doi: 10.1016/j.ejphar.2011.01.055
pubmed: 21315711
Gong X, Dan J, Li F, Wang L (2018) Suppression of mitochondrial respiration with local anesthetic ropivacaine targets breast cancer cells. J Thorac Dis 10(5):2804–2812. https://doi.org/10.21037/jtd.2018.05.21
doi: 10.21037/jtd.2018.05.21
pubmed: 29997943
pmcid: 6006047
Jose C, Hebert-Chatelain E, Dias Amoedo N, Roche E, Obre E, Lacombe D et al (2018) Redox mechanism of levobupivacaine cytostatic effect on human prostate cancer cells. Redox Biol 18:33–42. https://doi.org/10.1016/j.redox.2018.05.014
doi: 10.1016/j.redox.2018.05.014
pubmed: 29935387
pmcid: 6019688
Xing W, Chen DT, Pan JH, Chen YH, Yan Y, Li Q et al (2017) Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology 126(5):868–881. https://doi.org/10.1097/ALN.0000000000001528
doi: 10.1097/ALN.0000000000001528
pubmed: 28121635
Bezu L, Kepp O, Kroemer G (2022) Immunogenic stress induced by local anesthetics injected into neoplastic lesions. Oncoimmunology 11(1):2077897. https://doi.org/10.1080/2162402X.2022.2077897
doi: 10.1080/2162402X.2022.2077897
pubmed: 35602288
pmcid: 9116388
Freeman J, Crowley PD, Foley AG, Gallagher HC, Iwasaki M, Ma D et al (2018) Effect of perioperative lidocaine and cisplatin on metastasis in a murine model of breast cancer surgery. Anticancer Res 38(10):5599–5606. https://doi.org/10.21873/anticanres.12894
doi: 10.21873/anticanres.12894
pubmed: 30275177
Zhang X, Pang W, Liu H, Wang J (2019) Lidocine potentiates the cytotoxicity of 5-fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression. J Cell Biochem 120(10):16533–16542. https://doi.org/10.1002/jcb.28913
doi: 10.1002/jcb.28913
pubmed: 31081972
Li K, Yang J, Han X (2014) Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARbeta2 and RASSF1A demethylation. Int J Mol Sci 15(12):23519–23536. https://doi.org/10.3390/ijms151223519
doi: 10.3390/ijms151223519
pubmed: 25526566
pmcid: 4284778
Zheng Q, Peng X, Zhang Y (2020) Cytotoxicity of amide-linked local anesthetics on melanoma cells via inhibition of Ras and RhoA signaling independent of sodium channel blockade. BMC anesthesiology 20(1):43 1–9. https://doi.org/10.1186/s12871-020-00957-4
doi: 10.1186/s12871-020-00957-4
Zhu G, Zhang L, Dan J, Zhu Q (2020) Differential effects and mechanisms of local anesthetics on esophageal carcinoma cell migration, growth, survival and chemosensitivity. BMC Anesthesiol 20(1):126. https://doi.org/10.1186/s12871-020-01039-1
doi: 10.1186/s12871-020-01039-1
pubmed: 32450791
pmcid: 7249391
Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C et al (2019) Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun 10(1):1486. https://doi.org/10.1038/s41467-019-09415-3
doi: 10.1038/s41467-019-09415-3
pubmed: 30940805
pmcid: 6445096
Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V et al (2019) Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology 69(5):2048–2060. https://doi.org/10.1002/hep.30482
doi: 10.1002/hep.30482
pubmed: 30578687
Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M et al (2016) Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res 4(9):744–754. https://doi.org/10.1158/2326-6066.CIR-15-0156
doi: 10.1158/2326-6066.CIR-15-0156
pubmed: 27466265
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D et al (2017) Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66(3):545–551. https://doi.org/10.1016/j.jhep.2016.10.029
doi: 10.1016/j.jhep.2016.10.029
pubmed: 27816492